This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BASF (BASFY) Expands Sodium Methylate Capacity in South America
by Zacks Equity Research
This capacity increase is another step in BASF's (BASFY) business expansion for sodium methylate in South America, demonstrating the company's commitment to its customers and the South American biodiesel market.
Yara (YARIY) and Scatec Ink Renewable Ammonia Offtake Deal
by Zacks Equity Research
This project will bolster Yara's (YARIY) renewable ammonia sourcing portfolio and allow it to reliably serve its customers across several markets.
Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall
by Zacks Equity Research
Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure
Hawkins (HWKN) Strengthens Water Treatment With Wofford Buy
by Zacks Equity Research
Hawkins (HWKN) acquires Wofford Water Service, strengthening its presence in the southern U.S. and expanding its Water Treatment business in Mississippi.
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
by Zacks Equity Research
Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.
Sandstorm Gold (SAND) Posts Y/Y Preliminary Q2 Revenue Decline
by Zacks Equity Research
Sandstorm Gold's (SAND) preliminary revenues fall 16.9% year over year, while the cash operating margin improves 17.1% in the second quarter.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Arkema (ARKAY) Gets ISCC+ for Powder Coating Resins Facility
by Zacks Equity Research
The facility of Arkema (ARKAY) includes a polyester resin production line and a cutting-edge R&D laboratory dedicated to increasing the sustainability and performance of powder coating materials
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
Masimo (MASI) Fights Politan in a Bid to Retain CEO on Board
by Zacks Equity Research
Will Masimo (MASI) lose its CEO in its fight against activist investor Politan Capital Management? The company's management and employees want Joe Kiani to continue as the CEO.
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
by Zacks Equity Research
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
by Zacks Equity Research
Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.
BASF (BASFY) Partners ENGIE for Sustainable Biomethane Supply
by Zacks Equity Research
BASF (BASFY) and ENGIE sign an agreement to supply biomethane to Ludwigshafen and Antwerp sites, supporting sustainable manufacturing and reducing carbon footprints.
Commercial Metals (CMC) Bets on US Demand as Europe Market Ails
by Zacks Equity Research
Commercial Metals (CMC) gains from strong demand in North America for each of its primary product lines. However, market uncertainties in Europe remain a concern for the company.
Steel Dynamics (STLD) Declares Completion of Note Offering
by Zacks Equity Research
This transaction marks an important component of Steel Dynamics' (STLD) long-term plan to establish a solid capital foundation to support its team, customers, shareholders and future growth.
Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes
by Zacks Equity Research
Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
by Zacks Equity Research
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
Axalta (AXTA) Closes CoverFlexx Buy, Boosts Refinish Coatings
by Zacks Equity Research
Axalta Coating (AXTA) acquires The CoverFlexx Group to enhance its Refinish coatings offerings and support growth in the automotive refinish market.
Barrick's (GOLD) Kibali Mine to Sustain Annual Gold Production
by Zacks Equity Research
Barrick's (GOLD) Kibali mine sustains high production and leads in renewable energy, fostering regional growth and biodiversity.
DOW Announces Launch of Bio-Based NORDEL REN EPDM at DKT 2024
by Zacks Equity Research
NORDEL REN EPDM is set to provide a lower-carbon product by using bio leftovers from other industries as raw material, thus helping DOW customers in the rubber business.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan
by Zacks Equity Research
KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.
Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
by Zacks Equity Research
IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.